01/03/2017 13:01:00

GRAIL Closes Over $900 Million Initial Investment in Series B Financing to Develop Blood Tests to Detect Cancer Early

Financing led by ARCH Venture Partners with the largest investment by Johnson & Johnson Innovation; includes additional strategic industry and venture investors

GRAIL plans a second close with institutional investors to bring the total raised in the Series B to over $1 billion

MENLO PARK, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- GRAIL, Inc., a life sciences company whose mission is to detect cancer early when it can be cured, today announced that it has raised over $900 million through the first close of its previously announced Series B financing which was led by ARCH Venture Partners and includes Johnson & Johnson Innovation1 as the largest investor in the financing. The initial close also includes world-class strategic pharmaceutical, technology and financial investors. GRAIL anticipates a second close, with Goldman, Sachs & Co. acting as a placement agent, that will include additional institutional investors globally.

“We envision a global community that benefits from early-stage cancer detection where fewer individuals face the anguish of late-stage diagnosis and devastating outcomes,” said Jeff Huber, GRAIL’s Chief Executive Officer. “I believe that GRAIL’s approach leveraging high-intensity sequencing, population-scale clinical studies, and state of the art Computer Science and Data Science is unparalleled in the field of cancer detection. Our team made tremendous progress in 2016 and I look forward to additional clinical and strategic milestones.”

In addition to ARCH Venture Partners and Johnson & Johnson Innovation, the strategic investors participating in the first close include Amazon, Bristol-Myers Squibb, Celgene, McKesson Ventures, Merck (known as MSD outside the United States and Canada), Tencent Holdings Limited and Varian Medical Systems, Inc. GRAIL intends to close the remainder of the Series B investment prior to the end of the first quarter of 2017 from qualified investors.

“This cadre of world-class investors is a testament to their shared belief in our goal to reduce global cancer mortality through early detection,” said Ken Drazan, GRAIL’s Chief Business Officer. “Notably, the financing includes a broad spectrum of pharmaceutical and technology companies who, in the second close, will be joined by successful institutional investors in the life science space.”

GRAIL will use the proceeds of the financing for continued product development and validation of blood tests for early-stage cancer detection, including the previously announced Circulating Cell-free Genome Atlas (CCGA) study and other large-scale clinical trials that are expected to enroll hundreds of thousands of patients. The CCGA study will characterize the landscape of cell-free DNA profiles in individuals with cancer and in healthy non-cancer participants using GRAIL’s high-intensity (ultra-broad and ultra-deep) sequencing approach, leveraging Illumina sequencing technology. Some of the proceeds were used to repurchase a portion of Illumina’s stake in GRAIL such that Illumina now owns slightly less than 20 percent of the Company.

About GRAIL

GRAIL is a life sciences company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical trials, and state of the art Computer Science and Data Science to enhance the scientific understanding of cancer biology and develop blood tests for early-stage cancer detection. For more information, please visit www.grail.com.

About GRAIL’s High-intensity Sequencing Approach

GRAIL’s approach is to sequence circulating cell-free nucleic acids at unprecedented breadth and depth to optimize the detection of early-stage cancer. Combined with one of the largest clinical trial programs ever pursued in genomic medicine, GRAIL will be creating datasets of unprecedented scale to enable the deepest and most comprehensive understanding of cancer biology. GRAIL's technology infrastructure uses best in class computer science and data science approaches, with cloud-based infrastructure and rigorous software engineering practices. From the laboratory to the clinic, GRAIL’s goal is to produce the highest quality data and transform them into clinically actionable insights to save lives.

1 The Johnson & Johnson Innovation investment is made through an affiliate - Johnson & Johnson UK Treasury Company Limited.

GRAIL Contact:

Denise Powell

510.703.9491

denise@redhousecomms.com

pr@grail.com

Primary Logo

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
17 Sep
CHEMM
Mullen jeg tror du hænger meget fast i hvordan markedet så ud for ½ år tilbage. Vi har i mellemtiden..
34
17 Sep
 
Kære EI,   Jeg har stor forståelse for at i skal tjene penge, for at kunne ove ville udbyde de ydels..
23
18 Sep
DANSKE
Her er lidt om de Berlingske løgnhistorier o Danske Bank - for det tilfælde I har lyst til at anlægg..
22
13 Sep
SAS-DKK
Tænk hvis det var en kvinde eller etnisk minoritet der var blevet mobbet og truet så var de skinhell..
18
16 Sep
 
Jeg har skrevet til Nordnet at de bør beholde det gamle nordnet da jeg synes at det nye er noget bra..
16
12 Sep
 
Det nye Nordnet er uigennemskueligt, aktielisterne er uoverskuelige og generelt er platformens bruge..
16
12 Sep
CHEMM
Spørgsmålet er langt mere kompliceret end det lyder. Men Chemometec er en uendelig lille fisk i et m..
15
16 Sep
 
Det nye system er dybt uheldigt, både ifht. overblik - men også ifht. lay-out.    Nordnet kunne gøre..
13
12 Sep
PNDORA
Forstår ikke en rygende fis af det indlæg. En der venligst vil oversætte?
13
16 Sep
VELO
Velkommen til ugens faste tråd om Veloxis & Envarsus 😊   Det har været endnu en stille uge for Velo..
12

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Tyson Foods Launches Pact® Brand Refrigerated Snack Bites with Functional Benefits
2
CUMULUS MEDIA Announces Pricing of $525 Million Senior Secured Term Loan B
3
NCLA Refutes Cornell University’s Motion to Dismiss Its Former Professor’s Title IX Lawsuit
4
Associa Mid-Atlantic Selected to Manage the Perry Farm at Warrington Community
5
IMCD expands its Indian footprint by acquiring Monachem Additives

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
19 September 2019 06:14:31
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190829.2 - EUROWEB6 - 2019-09-19 07:14:31 - 2019-09-19 06:14:31 - 1000 - Website: OKAY